UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 7, 2019
Zynex, Inc.
(Exact name of Registrant as specified in its charter)
| Nevada | 001-38804 | 90-0275169 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
9555 Maroon Circle Englewood, Colorado |
80112 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (303) 703-4906
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b 2 of the Securities Exchange Act of 1934 (§240.12b 2 of this chapter).
Emerging Growth Company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| ITEM 8.01 | Other Events. |
On February 7, 2019, Zynex, Inc. issued a press release announcing the approval of its application to list its common stock on The Nasdaq Capital Market. The full text of the press release is furnished herewith as Exhibit 99.1.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
| d) | Exhibits . The following exhibits are filed with this report. |
| Exhibit No. | Description |
| 99.1 | Press Release issued by Zynex, Inc. announcing the approval of its application to list its common stock on The Nasdaq Capital Market |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Zynex, Inc. | |||
| Date: | February 7, 2019 | By: | /s/ Daniel Moorhead |
| Daniel Moorhead | |||
| Chief Financial Officer |
Exhibit 99.1
Zynex Announces Uplisting to The Nasdaq Capital Market
Englewood, CO February 7, 2019. Zynex, Inc . (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, is pleased to announce that its common shares have been approved to list on The Nasdaq Capital Market and is expected to begin trading under its existing symbol (ZYXI) on February 12, 2019.
“We are excited to reach this important milestone for Zynex. We have made significant progress over the past several years and uplisting to Nasdaq will help us communicate our story to a broader audience. We are now better positioned to attract institutional investors, which will fundamentally enhance the value of our company,” said Thomas Sandgaard, Founder, Chairman and Chief Executive Officer of Zynex.
About Zynex, Inc.
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices
used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke
and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.
For additional information, please visit:
www.zynex.com
.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or projections and as such are subject to numerous risks and uncertainties. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2017 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.
Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com